Back to results
US 2026/0226509 A1Published application
Crispr systems with engineered dual guide nucleic acids
AssigneesCelyntra Therapeutics SA, Danmarks Tekniske Universitet
InventorsRyan T. Gill, Tanya Warnecke, Andrea Barghetti, Line Dahl Poulsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
Claims20
An engineered, non-naturally occurring system comprising:
- (a) a targeter nucleic acid comprising, from 5′ to 3′:
- (i) a targeter stem sequence;
- and
- (ii) a spacer sequence designed to hybridize with a target nucleotide sequence;
- and
- (b) a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence,
- wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids, and wherein a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a Type V-A CRISPR Associated (Cas) protein that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA.
4 more elements
Dependencies are inferred from the claim text.